MeSH term
Frequency | Condition_Probility | Animals | 27 | 0.0 |
Cattle | 3 | 0.0 |
Cell Line | 14 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
*DNA Damage | 8 | 1.0 |
Humans | 84 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
Base Sequence | 16 | 0.0 |
Comparative Study | 11 | 0.0 |
Gene Library | 2 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
Research Support, Non-U.S. Gov't | 45 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Adult | 8 | 0.0 |
Biopsy | 2 | 0.0 |
*DNA Repair | 19 | 2.0 |
Middle Aged | 7 | 0.0 |
Pyrimidine Dimers/*metabolism | 12 | 70.0 |
Ultraviolet Rays | 19 | 2.0 |
Ducks | 5 | 29.0 |
Mice | 9 | 0.0 |
Phosphorylation | 2 | 0.0 |
*Viral Proteins | 2 | 1.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
In Vitro | 5 | 0.0 |
Xeroderma Pigmentosum/*genetics | 3 | 5.0 |
Aged | 3 | 0.0 |
Carboxypeptidase H | 4 | 14.0 |
Immunohistochemistry | 4 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Ultraviolet Rays/*adverse effects | 4 | 8.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Protein Binding | 6 | 0.0 |
Base Pair Mismatch | 2 | 1.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
*Genome, Human | 2 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Pyrimidine Dimers/metabolism | 6 | 33.0 |
Cockayne Syndrome/*genetics | 3 | 20.0 |
DNA/metabolism/radiation effects | 2 | 20.0 |
Dose-Response Relationship, Radiation | 9 | 2.0 |
Female | 8 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Hamsters | 4 | 0.0 |
RNA/biosynthesis | 2 | 2.0 |
Kinetics | 5 | 0.0 |
Skin/metabolism/*radiation effects | 3 | 37.0 |
*Ultraviolet Rays | 10 | 4.0 |
Cells, Cultured | 17 | 0.0 |
Transfection | 3 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Adolescent | 3 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
Peritoneal Dialysis/*adverse effects | 2 | 13.0 |
Reproducibility of Results | 3 | 0.0 |
DNA Damage | 11 | 1.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Male | 10 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
DNA Damage/*genetics | 2 | 3.0 |
Pyrimidine Dimers/*genetics | 3 | 60.0 |
Blood Preservation/*methods | 2 | 8.0 |
Apoptosis/radiation effects | 2 | 5.0 |
Transcription, Genetic | 6 | 0.0 |
Carboxypeptidases/*genetics | 3 | 13.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Pyrimidine Dimers | 4 | 44.0 |
Genes, p53 | 2 | 0.0 |
Pyrimidine Dimers/genetics | 2 | 100.0 |
Infant | 3 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Mutation | 5 | 0.0 |
Dimerization | 3 | 0.0 |
Protein Conformation | 2 | 0.0 |
DNA Repair/*genetics | 5 | 1.0 |
Fibroblasts | 4 | 0.0 |
Genetic Complementation Test | 2 | 0.0 |
Time Factors | 10 | 0.0 |
Keratinocytes/metabolism/*radiation effects | 2 | 18.0 |
Cell Survival | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Tetrahydrofolate Dehydrogenase/*genetics | 3 | 2.0 |
Reference Values | 2 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
*Proteins | 3 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Molecular Weight | 2 | 0.0 |
Rats | 4 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Models, Molecular | 4 | 0.0 |
DNA Repair/*physiology | 4 | 3.0 |
Fibroblasts/radiation effects | 3 | 10.0 |
Genes, p53/*radiation effects | 3 | 33.0 |
Binding Sites | 3 | 0.0 |
Conserved Sequence | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
*Sunlight | 2 | 14.0 |
Organ Specificity | 2 | 0.0 |
DNA Repair | 2 | 0.0 |
DNA/*radiation effects | 2 | 7.0 |
Radiation Dosage | 2 | 2.0 |
Blotting, Southern | 2 | 0.0 |
Deoxyribonuclease (Pyrimidine Dimer) | 2 | 8.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
Citrates | 2 | 14.0 |
*DNA Replication | 2 | 0.0 |
Fibroblasts/physiology/radiation effects | 2 | 50.0 |
Follow-Up Studies | 2 | 0.0 |
CHO Cells | 3 | 0.0 |
Genes, Structural | 2 | 0.0 |
Chlorophyll/*metabolism | 2 | 100.0 |
Adenine/pharmacology | 2 | 33.0 |
Heparin/pharmacology | 2 | 0.0 |
Solutions | 2 | 1.0 |
Mutagenesis | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Citrates/*pharmacology | 2 | 28.0 |
Glucose/*pharmacology | 2 | 2.0 |
*Blood Preservation | 5 | 8.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
*Blood Glucose | 2 | 18.0 |
Citrates/blood | 2 | 66.0 |
Glucose | 2 | 18.0 |
Phosphates/blood | 2 | 3.0 |
Adenine/*blood | 2 | 100.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Platelet Count | 2 | 0.0 |
Carboxypeptidases/*metabolism | 2 | 13.0 |
Protein Structure, Tertiary | 2 | 0.0 |